Bunion Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The bunion market reached a value of USD 567.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,018.8 Million by 2035, exhibiting a growth rate (CAGR) of 5.49% during 2025-2035.

The bunion market has been comprehensively analyzed in IMARC's new report titled "Bunion Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Bunion refers to a medical condition in which painful bony growth appears near the big toe joint on the inside of the foot. The disease is commonly characterized by osteoarthritis of the first metatarsophalangeal joint (that connects the toe to foot bones), diminished or altered range of motion, and discomfort with joint movement or while pressure is applied to the bump. The main symptoms of this illness include bone deformity, a bulging lump on the joint, stiffness, and pain. Individuals suffering from bunion may also experience redness, swelling or soreness, limited movement of the big toe, corns or calluses, inability to bend the big toe, difficulty wearing regular shoes, numbness, or irritation at the affected site, etc. The diagnosis of this ailment is typically based on the patient’s symptoms, medical history, and physical examination. The healthcare provider may also perform diagnostic procedures, including X-rays, to detect abnormalities in bone alignment or joint damage among patients.

The rising prevalence of excessive foot pronation, which can increase pressure on the toe and cause deformation of the joint's medial capsular structures, is primarily driving the bunion market. In addition to this, the escalating incidences of various associated risk factors, such as wearing high-heeled shoes, overly tight shoes, a family history of the bunion, foot stress, etc., are also bolstering the market growth. Moreover, the widespread adoption of non-steroidal anti-inflammatory drugs, including acetaminophen, ibuprofen, naproxen, etc., to reduce disease symptoms like pain and swelling is acting as another significant growth-inducing factor. Apart from this, the inflating application of custom-made foot orthotics, which aid in preventing further structural damage and control alignment issues, such as pronation in patients, is also propelling the market growth. Additionally, the increasing demand for massage and physical therapy that can break up soft-tissue adhesions and improve muscle strength to alleviate pain and inflammation is creating a positive outlook for the market. Furthermore, the emerging popularity of a 3D lapiplasty technique for treating the ailment, since it restores the normal alignment and improves unstable joint foundation by rotating it back into its original position and securing it permanently, is expected to drive the bunion market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bunion market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for bunion and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bunion market in any manner.

Recent Developments:

• In March 2024, Treace Medical Concepts, Inc. stated that 100,000 patients have been treated with their unique Lapiplasty 3D Bunion Correction System. The Lapiplasty Procedure allows doctors to repair all three planes of the bunion deformity and address the underlying cause by anchoring the unstable joint in the center of the foot with a proprietary mix of instruments, implants, and surgical techniques.
• In February 2024, Paragon 28, Inc. launched the PRECISION MIS Bunion System, which enables surgeons to perform a distal metatarsal osteotomy utilizing a minimally invasive (MIS) surgical approach.
• In September 2023, Stryker launched PROstep MIS Lapidus, a revolutionary internal fixation device designed to treat bunions through a minimally invasive surgical reduction of hallux valgus deformity and subsequent fusing of the first metatarsal cuneiform joint.

Key Highlights:

• A bunion deformity affects around 65 million Americans.
• The occurrence of bunions rises with age.
• This condition is more common in women than in men, most likely because of differences in foot architecture, footwear, and hereditary factors.
• Bunions are less common in children than in adults.
• Studies have indicated an incidence of up to 35% in the adolescent population.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bunion market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bunion market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bunion marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Bunion market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Bunion across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Bunion across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of Bunion across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Bunion by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Bunion by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Bunion by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with Bunion across the seven major markets?
• What is the size of the Bunion’ patient pool 2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of Bunion?
• What will be the growth rate of patients across the seven major markets?

Bunion: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Bunion drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Bunion market?
• What are the key regulatory events related to the Bunion market?
• What is the structure of clinical trial landscape by status related to the Bunion market?
• What is the structure of clinical trial landscape by phase related to the Bunion market?
• What is the structure of clinical trial landscape by route of administration related to the Bunion market?